| Name | Imlunestrant |
|---|
| Description | Imlunestrant (LY3484356) is an orally active selective estrogen receptor (ER) degrader (SERD). Imlunestrant (LY3484356) could be used in the study for ER+, HER2-advanced breast cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Imlunestrant (LY3484356) shows favorable efficacy and pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants[1]. Imlunestrant (LY3484356) is a potent degrader and selective pure antagonist of wild type and mutant ERα[2]. |
| References |
| Molecular Formula | C29H24F4N2O3 |
|---|---|
| Molecular Weight | 524.51 |